Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01165853 · ClinicalTrials.gov registry record · NA

Effects of Consuming Sugar-Sweetened Beverages With Meals for 10 Weeks

A NA study of Insulin Resistance and Metabolic Syndrome, sponsored by University of California, Davis.

Completed
Registry status
NA
Development phase
32
Enrollment target
1
Study location

NCT01165853 is a NA study of Insulin Resistance and Metabolic Syndrome that has completed, run by University of California, Davis. The registered enrollment target is 32 participants, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01165853, a NA study of Insulin Resistance and Metabolic Syndrome, has completed, sponsored by University of California, Davis.

COMPLETED
Registry status
NA
Development phase
32 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is compare the effects of consuming glucose- and fructose-sweetened beverages on appetite, body weight, body fat, and the amount of energy the body burns as well as effects on blood pressure, hormones, blood triglycerides and cholesterol, and the body's sensitivity to the insulin.

Interventions

  • OTHER Glucose
  • OTHER Fructose

Study Locations (1)

California

  • Clinical Research Center - Sacramento

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2005-07
Est. Completion 2012-07
Phase NA

Sponsor

University of California, Davis

657 total trials

What the Registry Record Tells You About NCT01165853

The ClinicalTrials.gov registry entry for NCT01165853 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (87% lower). The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Insulin Resistance appearing as the primary indexed condition, and to 2 interventions - of which Glucose is the first listed.

NCT01165853 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT01165853 about?

NCT01165853 is a clinical study titled "Effects of Consuming Sugar-Sweetened Beverages With Meals for 10 Weeks". The purpose of this study is compare the effects of consuming glucose- and fructose-sweetened beverages on appetite, body weight, body fat, and the amount of energy the body burns as well as effects on blood pressure, hormones, blood triglycerides and cholesterol, and the body's sensitivity to the i...

What is the current status of trial NCT01165853?

This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2005-07. Estimated completion is 2012-07.

What conditions does trial NCT01165853 study?

This clinical trial studies the following conditions: Insulin Resistance, Metabolic Syndrome, Dyslipidemia.

What interventions are being tested in trial NCT01165853?

The interventions under investigation include: Glucose (OTHER), Fructose (OTHER).

Who is sponsoring clinical trial NCT01165853?

This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01165853 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Insulin Resistance

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.